The pain won't stop. GSK ends the week with a slap­down on its Nu­cala ap­pli­ca­tion for COPD

Glax­o­SmithK­line $GSK just com­plet­ed an un­nec­es­sary and em­bar­rass­ing lap at the FDA with a fresh slap­down.

At a time the com­pa­ny is hop­ing to be­gin to demon­strate that the phar­ma R&D group has be­gun a long-await­ed turn­around, the FDA just com­plet­ed its lat­est hu­mil­i­a­tion on a new ap­pli­ca­tion for Nu­cala with a wide­ly ex­pect­ed com­plete re­sponse let­ter.

In a short state­ment out late Fri­day, the phar­ma gi­ant not­ed:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER